ID   SpEEE
AC   CVCL_WS47
SY   SpEEE #87-29; 87-29
DR   Wikidata; Q98132813
RX   Patent=US7608425;
RX   PubMed=21473000;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Patented cell line.
CC   Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transfected with: HGNC; 990; BCL2 (with p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE).
CC   Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
DI   NCIt; C125417; Mouse plasma cell myeloma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
SX   Female
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 21-03-23; Version: 4
//
RX   Patent=US7608425;
RA   Goldenberg D.M., Chang C.-H., Rossi E.A., Nordstrom D.;
RT   "Methods for protein expression in mammalian cells in serum-free
RT   medium.";
RL   Patent number US7608425, 27-Oct-2009.
//
RX   PubMed=21473000; DOI=10.1002/btpr.584;
RA   Rossi D.L., Rossi E.A., Goldenberg D.M., Chang C.-H.;
RT   "A new mammalian host cell with enhanced survival enables completely
RT   serum-free development of high-level protein production cell lines.";
RL   Biotechnol. Prog. 27:766-775(2011).
//